Glycemic control of children and adolescents must be assessed by both quarterly HbA1c and by regular home glucose monitoring. These permit achieving optimal health by:
• determining with accuracy and precision an individual's glycemic control, including assessment of each individual's glycemic determinants (A),
• reducing the risks of acute and chronic disease complications (A),
• minimizing the effects of hypoglycemia (A) and hyperglycemia (B) on brain development, cognitive function, mood; and
• optimizing quality of life (E).
Recommendations:
• Regular self-monitoring of glucose (using accurate fingerstick BG measurements, with or without CGM or isCGM), is essential for diabetes management for all children and adolescents with diabetes (A).
o Each child should have access to technology and materials for self-monitoring of glucose measurements to test enough to optimize diabetes care (B).
o Diabetes center personnel should advocate to nations, states, and health care funders to ensure that children and adolescents with diabetes have adequate glucose monitoring supplies (E).
o When fingerstick BGs are used, testing may need to be performed 6-10 times per day to optimize intensive control. Regular review of these BG values should be performed with adjustments to medication/nutritional therapies to optimize control
(B).
o Real-time CGM data particularly benefit children who cannot articulate symptoms of hypoglycemia or hyperglycemia and those with hypoglycemic unawareness (A).
o isCGM can complement fingerstick BG assessments. Although isCGM provides some similar benefits to CGM, it does not alert users to hypoglycemia or hyperglycemia in real time, nor does it require calibration. Without robust pediatric use efficacy data, it cannot fully replace BG monitoring (B).
• For children, adolescents and young adults aged ≤25 years we recommend individualized targets, aiming for the lowest achievable HbA1c without undue exposure to severe hypoglycemia balanced with quality of life and burden of care (E).
• For children, adolescents and young adults ≤25 years who have access to comprehensive care a target of HbA1c of <53 mmol/mol (7.0%) is recommended (E).
o A higher HbA1c goal (in most cases <58 mmol/mol (7.5%)) is appropriate in the following contexts:
 inability to articulate symptoms of hypoglycemia  hypoglycemia unawareness/history of severe hypoglycemia  lack of access to analog insulins, advanced insulin delivery technology, ability to regularly check blood glucose (BG), and CGM (E), and  individuals who are 'high glycators,' in whom an at-target HbA1c would reflect a significantly lower mean glucose than 8.6 mmol/l (155 mg/dl) (E) o A lower goal (6.5%) or 47.5 mmol/mol may be appropriate if achievable without excessive hypoglycemia, impairment of quality of life, and undue burden of care
(E).
o A lower goal may be appropriate during the honeymoon phase of type 1 diabetes
o For patients who have elevated HbA1c, a step-wise approach to improve glycemic control is advised including individualized attention to:
 personal factors limiting achievement of the target (E),  assessment of the psychological effect of goal setting on the individual (E), and  incorporation of available technology to improve glucose monitoring and insulin delivery modalities (E).
• HbA1c measurement should be available in all centers caring for persons with diabetes
(B).
o HbA1c measurements should be performed at least every 3 months (B).
o Examining variations in HbA1c between centers can assist in evaluating the care provided by health care centers including compliance with agreed standards to improve therapies and delivery of pediatric diabetes care (B).
General principles determining glycemic targets
HbA1c reflects mean BG over the prior three to four months and is currently the only long-term glycemic control measure with robust outcome data. Multiple studies in diverse populations have shown that elevated HbA1c values are associated with chronic complications of diabetes.
Intensive management resulting in lower HbA1c concentrations is associated with fewer and delayed development of microvascular and macrovascular chronic complications [1] [2] [3] [4] [5] , see Chapter 18 (ref) . Additionally, lower HbA1c shortly after diagnosis is associated with a lower risk of subsequent complications 6, 7 . Follow-up data from the DCCT indicate that 5 -7 years of improved glycemic control, including during adolescence and young adulthood, decreased the risk for microvascular and macrovascular complications [8] [9] [10] [11] and mortality 12 in subsequent years.
Chronic hyperglycemia has adverse effects on neurocognitive function and brain structure and development in children and adolescents with diabetes [13] [14] [15] [16] [17] . Chronic hyperglycemia and large glucose fluctuations during the years of rapid brain development affect brain structure and development, including impairment of the growth of the hippocampus. These observations call into question the prevalent practice of tolerating some hyperglycemia to minimize the risk of hypoglycemia in young children with T1D 18, 19 . Hypoglycemia is also a significant risk for . Sometimes these differences are due to conditions that alter the life span of red blood cells or changes in hemoglobin glycation, such as sickle cell disease or anemia. In addition, genetic differences in hemoglobin glycation are also present [33] [34] [35] . In a recent report from the US that identified individuals as "black" or "white" based upon self-report, blacks had mean HbA1c values 4.4 mmol/mol (0.4%) higher than whites for the same mean glucose concentration determined using CGM 32 . As indicated below, in this study, race may be a surrogate marker for genetic factors that determine the relationship between mean BG and HbA1c.
Additionally, several studies have shown significant differences between HbA1c and observed self-monitored glucose values between individuals without obvious medical or racial/ethnic biologic differences 33, 36 . 
Monitoring of glycemic control
Home self-monitoring of glucose:
• tracks immediate and daily levels of glucose control [39] [40] [41] [42] ;
• helps to determine immediate and ongoing basal and bolus insulin requirements;
• detects hypoglycemia and assists in its management;
• assists in the appropriate management of hyperglycemia; and
• helps guide insulin adjustments to decrease glucose fluctuations.
Fingerstick BG measurements
Greater frequency of fingerstick glucose monitoring is associated with lower HbA1c in persons with type 1 diabetes 25, [39] [40] [41] [42] . HbA1c improvements with more frequent glucose measurements are due to better insulin dosing for carbohydrate consumed and an improved ability to quickly correct out-of-target range glucose values. In addition, early detection of decreasing glucose values before symptomatic hypoglycemia occurs permits more precise correction with a decreased risk of overcorrection and resultant hyperglycemia. Self-monitoring of glucose around exercise also allows improved insulin management and a decreased risk for hypoglycemia during and following exercise 43 .
Equipment. There are many types of BG meters; however, significant inaccuracy may arise from operator-related errors 44, 45 . Health care professionals should choose and advise on types that are robust, precise, accurate, and familiar to them as well as affordable to the person with diabetes. Devices that do not require calibration/coding may be easier to use. Low quality devices, offered sometimes to reduce cost, may compromise safety owing to lack of accuracy.
High industry standards, including accuracy, precision and ability to download and analyze data should be upheld by regulatory agencies. Industry standards state that 95% of readings should be within ±15% of the reference value 46 . ISPAD recommends exclusive use of glucose meters that achieve this standard.
Timing of Self-Monitoring of Glucose:
BG is best measured:
• during the day, before meals and snacks;
• at other times (e.g. 2-3h after food intake) to determine appropriate meal insulin doses and show levels of BG in response to the action profiles of insulin (at anticipated peaks and troughs of insulin action).
• in association with vigorous exercise (before, during and several hours after) so that changes may be made in glycemic management 43, 47 ;
• at bedtime, during the night and on awakening to detect and prevent nocturnal hypoglycemia and hyperglycemia as well as optimize basal insulin;
• before driving a car or operating hazardous machinery;
• to confirm hypoglycemia and to monitor recovery; and
• during intercurrent illness to prevent hyperglycemic crises.
The number and regularity of fingerstick BG measurements should be individualized depending on:
• availability of equipment;
• type of insulin regimen; and
• ability of the child to identify hypoglycemia.
Successful intensive diabetes management requires self-monitoring of glucose at least six to ten times a day and regular, frequent review of the results to identify patterns requiring adjustment to the diabetes treatment plan 42, 48 . This includes review by the person with diabetes and their family in addition to consultation with the diabetes care team.
Glucose targets throughout the day should correspond with individualized HbA1c targets (Table 1) . Empiric data in pediatrics on which to base glucose targets and how this relates to HbA1c are needed. In the absence of such data, we advocate personalizing the above glucose targets to achieve an HbA1c of <53 mmol/mol (7.0%). Consistent targets, communication and teamwork are important in improving HbA1c [49] [50] [51] . See Table 1 for recommended glucose targets to achieve an HbA1c of <53 mmol/mol (7.0%), although these need to be individualized based on patient and clinic characteristics.
Continuous glucose monitoring (CGM) (See also Technology Chapter)
CGM uses minimally invasive devices that measure subcutaneous interstitial fluid glucose every 1 -5 minutes, i.e., 'continuously'. All devices permit BG targets to be set so that an alarm will alert the wearer to a glucose value projected to fall below or rise above the target in 10 -30 min, based on the rate of change of the interstitial glucose 52, 53 . Newer devices have a mean average relative difference (MARD) of <10% and, therefore, a similar accuracy to that of capillary BG meters 54 .
CGM is a much more sophisticated approach than home fingerstick BG monitoring as it can also identify times of consistent hyperglycemia and times of increased risk for hypoglycemia.
Days with outlier glucose values can also be more readily identified. CGM may particularly benefit those with hypoglycemic unawareness, as the devices will alarm when glucose is below a specified level or with a rapid rate of fall of glucose 55, 56 . With short-term use of sensors, mean glucose values decrease, and time spent in the hypoglycemic range also decreases 57, 58 .
CGM use has been associated with lower HbA1c compared to fingerstick BG measurements alone; and greater improvements in HbA1c correlate with increasing hours per week of CGM use 52, 59, 60 .
CGM can be used in "blinded" or "real time" modes. Blinded CGM provides retrospective data and is generally only useful for clinical research or for insulin adjustment by a health care provider 61 . Real-time CGM use with immediate corrections to keep glucose levels in range has been shown to more effectively improve glycemic control than 'blinded' collection of data analyzed by a health provider at a later time 62 . Appropriately calibrated CGM devices and an isCGM device are now approved for real-time non-adjunctive (replacement of fingerstick monitoring) use in some settings, although depending on the accuracy and labeling of the technology used, some CGM values must still be confirmed by fingerstick BG monitoring 63 .
However, periodic downloads allow the person with diabetes and/or their caregiver and health care provider to review a larger amount of data and make more comprehensive adjustments 64 .
Review of CGM data is a very helpful tool to teach patients about the effects of food, insulin timing, and exercise on glucose levels. The intermittent, delayed readout, often using blinded modes, has been helpful as a diagnostic tool and for management of hyperglycemia in special 9 groups, e.g., those with pre-type 1 diabetes 65 , monogenic diabetes 66 or cystic fibrosis-related diabetes 67, 68 . CGM studies have informed recommendations for insulin management for all individuals with diabetes including those not using continuous sensing devices 69, 70 .
Current limitations of real-time CGM include economic and behavioral barriers and the still imperfect accuracy and difficulty with wearability of some sensors that may discourage routine use. Currently, these devices, while approved for pediatric use, are expensive and may not be available in many countries. Insurance coverage may also be limited. Over time, these devices will continue to become more widely available and better coverage by both national and private insurance is anticipated. ISPAD advocates for increased availability of CGM for children, adolescents and young adults with diabetes.
While real-time CGM is beneficial both in persons using multiple daily injections and insulin pumps, its use in combination with an insulin pump is generally more effective 71 , particularly when the CGM is integrated into a sensor-augmented pump 72 . Early studies of longer-term CGM use (6 months) found that, despite benefiting from similar reduction in HbA1c, children and adolescents may not be willing to wear a device as often, or for as prolonged a period of time as needed to consistently improve glucose control 73 . Not surprisingly, the frequency of sensor use predicts the HbA1c lowering associated with CGM 60, 74 . These observations indicate that additional work is needed to develop technology that is better tolerated and less intrusive in teenagers' lives and to identify ways to help adolescents adapt to healthcare tasks required to maintain near-normal glucose levels. Early negative experiences with inaccurate sensors, devices that were not easy to wear, and high costs, may have discouraged some individuals from long-term use 75, 76 . These perceptions appear to now be changing due to major improvements in sensor technology and to re-training users Glucose variability may also contribute to the risk for complications independently of HbA1c [78] [79] [80] . It has been suggested that the coefficient of variation (the standard deviation of the BG values divided by the mean) may be the most descriptive of overall excursions and that "stable" glucose values can be defined as having coefficients of variation <36% with values greater than this being "unstable" 79 . Standardized metrics for analysis and reporting of these data have been proposed, including an ambulatory glucose profile (AGP) showing data as a modal day.
Few data are yet available as to how these metrics relate to long-term outcomes for persons with diabetes, particularly for children 79 .
Intermittently scanned CGM
In many settings CGM may not be available for use by children. Intermittently scanned CGM (isCGM) is another way to measure glucose that has been successfully used in children 81 .
Current systems provide sensor wear up for up to 14 days and require no user calibration.
isCGM has similarities with CGM but is a simpler and more economical technology 79 . Current commercially available isCGM technology has two versions, a personal and a professional format. The former uses a sensor inserted in the back of the upper arm and a separate touchscreen reader device. When the reader is swiped over the sensor, the sensor transmits an instantaneous interstitial glucose level, trends over the last 15 minutes, and a graph showing glucose data for the preceding eight hours. However, if the system is not scanned for more than eight hours, any information more than eight hours old is lost. The ambulatory glucose profile for the last 90 days is stored in the reader and can be easily downloaded. When analyzed in real-time or retrospectively, the data generated by the isCGM system are like that of real-time CGM. The main differences are that isCGM does not provide high or low glucose alarms, require or permit calibration, or control insulin infusion rates when used with a pump.
The professional format uses the same sensor technology as the personal version. Interstitial glucose is recorded every 15 minutes for 14 days; however, the data are blinded from the user.
A health professional needs to wave the reader over the sensor to retrieve the information for download. The professional format is useful as an aid to understanding disparities in HbA1c levels and BG assessments and for retrospective assessment of glycemic control.
The system has acceptable accuracy compared with capillary BG measurements [82] [83] [84] [85] , which has led to approval of both versions in more than 30 countries Advances in pump and CGM technology have led to the development of pumps that adjust 11 insulin delivery based on ambient interstitial glucose using computerized algorithms. These are important steps toward "closing the loop" and an eventual true artificial pancreas system.
Such devices reduce the risk of severe and moderate hypoglycemia, particularly overnight, and hold promise to reduce the burden of care and improve glucose control 56, 88 . Further details are available in the chapter Diabetes Technologies [ref] .
Record Keeping
• It is common practice for a monitoring diary, logbook, spreadsheet, smart meter, app, or cloud-based program to be used to record patterns of glycemic control, insulin doses and amounts of carbohydrate consumed, and adjustments to treatment. These data should be reviewed regularly by the person with diabetes and family.
• The record book or data from the electronic device/cloud is required at the time of • Glucose monitoring records should not be used judgmentally but as a vehicle for discussing the causes of variability and strategies for improving glycemic control.
• Frequent home review of records to identify glycemic patterns is required for successful intensified diabetes management.
Hemoglobin A1c (HbA1c)

Glycated hemoglobin
• Glucose is irreversibly attached to hemoglobin while the red blood cells circulate (with a life span of approximately 120 days) forming glycated hemoglobin (HbA1 or HbA1c).
• HbA1c reflects glycemia over the preceding 4 -12 weeks, weighted toward the most recent 4 weeks. However, the most recent week is not included because the most recent glycation is reversible 89 .
The HbA1c assay provides an objective, long-term measure of glycemia and revolutionized diabetes management. There is a strong correlation between HbA1c and BG and CGM glucose 31, 33 . The International Federation of Clinical Chemistry (IFCC) has developed a reference method that precisely measures glycated HbA1c only 90, 91 . The reference measurement procedure has been defined as bN1-deoxyfructosyl-hemoglobin, and the recommended SI measurement units are mmol/mol 92 . IFFC/ADA/EASD/IDF has issued a consensus statement regarding this standardization process 92 . A calculator for conversion between the DCCT/NGSP % units and the IFCC/SI mmol/mol units can be found at http://www.ngsp.org/convert1.asp
Equipment and facilities.
• Facilities for HbA1c measurement should be available to all centers caring for young people with diabetes.
• Every child should have a minimum of four measurements per year (at approximately 3-month intervals) 93, 94 .
• Capillary blood collection is preferable. It is also preferable that the HbA1c result is available at the time of the medical visit so that immediate adjustments in management can be based on the HbA1c level along with available glucose data.
• A reference range for non-diabetic children should be available.
• There should be regular quality control comparisons with national and DCCT or IFCC standards. It is recommended that scientific papers provide HbA1c in both DCCT/NGSP and IFCC/SI units.
Fructosamine and other glycated products.
Fructosamine measures the glycation of serum proteins such as albumin and reflects glycemia over the preceding 3 -4 weeks. It is therefore used for the assessment of shorter periods of control than HbA1c. Fructosamine or glycated albumin may be useful in monitoring glucose control in individuals with abnormal red cell survival time. Fructosamine and other glycated products have been recently evaluated as predictors of the development of vascular 13 complications. In DCCT/EDIC, glycated albumin and HbA1c had similar associations with retinopathy and nephropathy, which were strengthened when both measures were considered together. Only HbA1c was significantly associated with development of cardiovascular disease 95 . The Atherosclerosis Risk in Communities (ARIC) study that included adults with type 1 and type 2 diabetes found that fructosamine and glycated albumin were associated with microvascular complications with prognostic value comparable to HbA1c 96 .
HbA1c targets
Goals for children, adolescent, and young adults (aged ≤25 years) with type 1 diabetes should be individualized (Table 1) . A target of 53 mmol/mol (7.0%) is recommended for persons who have access to analog insulins, advanced insulin delivery technology, and the ability to regularly check BG and/or use CGM. Higher HbA1c goals, <58 mmol/mol (7.5%), are appropriate for most persons in the following contexts: inability to articulate symptoms of hypoglycemia, hypoglycemia awareness, history of severe hypoglycemia, high glycators, and in resource-limited environments.
The HbA1c value of 7% (53 mmol/mol) is chosen with the aim of avoiding long-term microvascular and macrovascular complications of diabetes while also avoiding severe hypoglycemia and the adverse central nervous system changes associated with both hypoglycemia and hyperglycemia. Evidence from the DCCT is available for adolescents, and recommendations for younger children are extrapolated from these data and are based on expert opinion. It is important to note that the intensively treated adolescent cohort of the DCCT achieved a mean HbA1c of 65 mmol/mol (8.1%), while those in the corresponding adult cohort achieved a mean HbA1c of 54 mmol/mol (7.1%) 100, 101 . Similarly, several registries and individual clinics report reduction in mean HbA1c over time highlighting the importance of benchmarking, quality improvement, and a team approach to improving glucose control 25, 102 . In the well-educated EDIC adult cohort, which has excellent access to the newest diabetes technology and a mean age of 45±7 years, the most recent mean HbA1c was 62 mmol/mol (7.8%) 97 . Acute and chronic complication rates are also decreasing with improvements in care 27, 103 .
Of all age-groups, adolescents are currently the farthest from achieving a HbA1c goal of <58 mmol/mol (7.0%) 6, 77 , reflecting the sub-optimal diabetes management that frequently accompanies the increased independence in diabetes care during the adolescent years, as well as the effects of the psychological and hormonal milieu of adolescence. However, given that results from DCCT/EDIC document that elevated HbA1c for 5 -7 years, which is similar to the duration of puberty, may have prolonged adverse effects 8,10,104,105 caregivers should not be complacent with the care of these youth, but work to improve glycemic control as much as possible. While better insulins, glucose monitoring, and insulin delivery devices are available today, compared with the DCCT era, adolescents in general may still be unable to achieve a lower HbA1c levels than the DCCT adolescent average without novel approaches to care.
Sometimes, particularly for adolescents, "aiming for lower" is needed rather than moving all the way to recommended targets to reduce burnout and loss-to-follow up. Too ambitious goals may lead to discouragement and a sense of failure and alienation for many teens. The aspirational HbA1c goal of <53 mmol/mol (7%) is most appropriate in resource-intensive settings where access to analog insulins, advanced insulin delivery systems, and state-of-the art glucose monitoring technology are available. Goals even lower than 53 mmol/mol (7.0%) may also be appropriate for those children with significant residual beta cell function who may 15 be able to achieve an HbA1c within the non-diabetic reference range. This condition is most likely seen in the first year after diagnosis (during the partial remission or "honeymoon" phase),
generally between 1 and 6 months after diagnosis.
Organizations such as the National Institute for Health and Care Excellence and the Swedish National guidelines have recommended uniformly lower goals for children and adolescents with type 1 diabetes 106, 107 . However, these guidelines are based on the likelihood of complications in adults and admit that there is "no evidence" in children for this decrease 107 .
There is no evidence that these lower goals can be achieved safely, how much of a reduction in future complications they might afford, or that they do not result in significant reductions in quality of life and in increased stress/distress. Also, it is still not yet known precisely how a HbA1c of 48 mmol/l (6.5%) compared to <53 mmol/l (7%), particularly in the years before puberty, will be associated with subsequent reductions in micro-or macro-vascular disease as data on the relationship between HbA1c in the pre-pubertal years and future vascular complications are mixed 108, 109 .
Careful attention must be taken to avoid severe hypoglycemia. Although older studies suggested an increased risk for hypoglycemia with lower HbA1c 1, 2, 110, 111 , in recent years this has not been the case, in part due to increased use of insulin analogs, and insulin pump therapy, with or without CGM 21, 23, 24, 28, 77, 112, 113 . Because severe hypoglycemia is more common in patients with hypoglycemia unawareness, glucose targets must be increased when hypoglycemia unawareness occurs 114 . CGM devices, especially when coupled with pumps equipped with low glucose suspend, may also particularly benefit those with hypoglycemia unawareness, as the devices will alarm when glucose is below a specified range or with rapid rate of fall of glucose and temporarily suspend insulin delivery 55, 56, 115 . Hypoglycemia unawareness is more common in those who maintain generally lower BG levels 116, 117 .
Health care priorities and future directions:
Persons with type 1 diabetes, their families, health care providers, and others (e.g. insurers)
should be aware that achieving an HbA1c consistently at or below the target range without extensive personal and national health care resources and outside of a clinical trial structure may be very difficult. The observed differences in HbA1c and other metrics across centers and countries indicate that additional work in quality improvement (with de-anonymized center-and region-specific data) with attention to best practices in care is needed [118] [119] [120] . 
